Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) EPS (Weighted Average and Diluted): 2018-2024

Historic EPS (Weighted Average and Diluted) for Voyager Therapeutics (VYGR) over the last 7 years, with Dec 2024 value amounting to -$1.13.

  • Voyager Therapeutics' EPS (Weighted Average and Diluted) fell 193.75% to -$0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.17, marking a year-over-year decrease of 433.85%. This contributed to the annual value of -$1.13 for FY2024, which is 138.05% down from last year.
  • Per Voyager Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.13 for FY2024, which was down 138.05% from $2.97 recorded in FY2023.
  • In the past 5 years, Voyager Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $2.97 in FY2023 and a low of -$1.89 during FY2021.
  • For the 3-year period, Voyager Therapeutics' EPS (Weighted Average and Diluted) averaged around $0.21, with its median value being -$1.13 (2024).
  • As far as peak fluctuations go, Voyager Therapeutics' EPS (Weighted Average and Diluted) crashed by 292.86% in 2021, and later surged by 345.45% in 2023.
  • Voyager Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at $0.98 in 2020, then tumbled by 292.86% to -$1.89 in 2021, then surged by 35.98% to -$1.21 in 2022, then soared by 345.45% to $2.97 in 2023, then tumbled by 138.05% to -$1.13 in 2024.